CONNECT WITH US:
Source: Avance Clinical
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials
Adelaide, AUS, 2020年03月20日 - (JCN Newswire) - Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials.
Avance Clinical offers 20-years of experience in the CRO sector, and has conducted vaccine and infectious diseases trials in the past 5 years. Avance is clearly the CRO of choice for trials targeting COVID-19.
"Importantly, the more than 40% R&D cash rebate from the Australian Government and the attractive current exchange rate, makes Australia one the most cost-effective destinations for conducting clinical trials," said Avance Clinical CEO Yvonne Lungershausen.
Australia's reputation for scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for current COVID-19 trials.
"Our depth of expertise and knowledge in the area makes us the CRO of choice for any biotech looking to develop treatments for COVID-19," said Ben Edwards, Avance's Chief Strategy Officer.
"It is also very important to emphasise that based on current trends, Australia is likely to be one of the countries least affected by COVID-19.
We anticipate that this sets the scene for the least amount of disruption to clinical trial activities over the period in which the world adjusts to the situation created by COVID-19."
Ms Lungershausen said in general terms, we do not anticipate significant disruption to the progress and timelines for the projects we are currently managing across all therapeutics indications. "Our team's experience in working with remotely based clients and clinical service providers and our virtual communication systems and processes place us in a clear position of strength in maintaining the momentum for our current projects," she said.
"Our team is very much accustomed to remote communication and management of projects," said Mr Edwards.
Clinical research sites in Australia have already responded to the challenges of the COVID-19 pandemic, putting measures and systems in place which aim to safeguard the interests of their patients and the general public, while also seeking to minimise disruption to clinical research activities.
The Avance Clinical operations team maintains constant communication with trial sites, receiving the latest information on ongoing changes in procedures and effectively managing the activities relating to the projects being managed by Avance.
"Avance Clinical has a range of tools available to support the sites and our clients to successfully complete their trials during this challenging time. These will be carefully managed to ensure study compliance," said Ms Lungershausen.
For more information about the benefits of running your next study in Australia contact us:
About Avance Clinical
Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:
- Access to independent Phase 1 facilities across Australia including hospital-based units for critical care
- Dedicated Investigators committed to clinical research
- Major hospitals with world class infrastructures and dedicated Clinical Trial Units
- Expedited clinical trial start-up timeframes
セクター: バイオテック・製薬, 健康・医薬品
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
TOYOTA GAZOO Racing to Make Virtual Le Mans Debut
Jun 05, 2020 17:34 JST
Toyota Mobility Foundation to Expand Provision of Connected and Sanitized Mobility Services to support Healthcare in Indonesia in Support of the Fight against COVID-19
Jun 05, 2020 17:22 JST
Six Companies Establish R&D Joint Venture for Commercial Vehicle Fuel Cell Systems for the Creation of a Hydrogen-based Society in China
Jun 05, 2020 17:01 JST
Singapore's LABMED shipped over 20 million masks to meet global demand
Jun 04, 2020 22:00 JST
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
Jun 04, 2020 11:43 JST
NEC's Netcracker 2020 Puts Service Providers at the Center of the Digital Economy
Jun 04, 2020 09:15 JST
Rakuten Mobile and NEC Agree to Jointly Develop Containerized Standalone 5G Core Network
Jun 03, 2020 10:34 JST
The Toyota Mobility Foundation and Partners Establish Digital Platform to Help Support People and Industry in Rural Germany
Jun 03, 2020 09:05 JST
Mitsubishi Corporation and NTT complete investment in HERE Technologies
Jun 02, 2020 14:54 JST
Toyota Announces its Line-up for the New GR Yaris in Japan
Jun 02, 2020 13:35 JST
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
Jun 02, 2020 11:05 JST
MHI RJ Aviation Group Launches as Mitsubishi Heavy Industries Ltd. Closes Acquisition of CRJ Series Program From Bombardier Inc.
Jun 02, 2020 10:23 JST
LEXUS previews the New IS
Jun 02, 2020 09:12 JST
DENSO and Certhon Establish DENSO AgriTech Solutions
Jun 01, 2020 12:48 JST
Fujitsu Signs Partnership Agreement with Scaled Agile, Inc., Driving Large-Scale Agile for Digital Transformation
Jun 01, 2020 12:01 JST
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST
Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST
DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST
Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST
More Latest Release >>